AMARIN CORP. PLC REG.SHS(SP.ADRS NEW)/1 LS-,50 (WK

globenewswire.com/news-release/2019/01/23/...fic-Session.html

First and foremost, Vascepa now appears like it could be a straightforward and cost-effective way to significantly decrease mortality rates among patients with stubbornly high triglyceride levels. As proof, Vascepa reportedly retails for $349 for a 30-day supply, which pales in comparison to the cost of an extended hospital stay stemming from a heart attack or stroke.  

Secondly, Vascepa has the potential to enter one of the largest and most lucrative markets in all of healthcare following these stellar late-stage trial results. Several of the best-selling medications of all time, after all, target patients prone to developing cardiovascular disease. So, while Vascepa's current peak sales projection of $2.5 billion is certainly nothing to sneeze at, this novel fish oil pill may even go on to surpass this stately sales estimate within the next five to 10 years.

Bottom line: Amarin seems destined to continue its recent growth spurt, thanks to Vascepa's outstanding top-line results in REDUCE-IT. As such, bargain-hunters might want to scoop up some shares soon.  

seekingalpha.com/article/...ear-timeframe-70-percent-downside

Der ist nicht negativ eingestellt sondern ein basher und Faktenverdreher, dem wurde die Arztlizenz entzogen und jetzt ist er ein armseeliges Vehicel der shorts....lächerlich!

Amarin: A Rebuttal To Omega-3 Fans

Jan. 30, 2019 3:55 PM ET|61 comments | About: Amarin Corporation PLC

... (automatisch gekürzt) ...

seekingalpha.com/article/...amarin-rebuttal-omegaminus-3-fans

Neue Rekordverschreibungszahlen:

TRx: 37,934{vs 36,875;+2.87%}Sec+0.27% ATH NRx: 17,624{vs 16,563;+6.41%}Sec+2.34% ATH Ref: 20,310{vs 20,312;-0.01%}Sec-1.36% 2ndATH

Novartis (NVS) Rumored to Be in Talks to Acquire Amarin (AMRN) - Source
February 22, 2019 9:59 AM
Novartis (NYSE: NVS) is rumored to be in talks to acquire Amarin Corp. (NASDAQ: AMRN), according to a source claiming ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Vllt schon diesen Monat  

Amarin meldet Zahlen für 2018

• Umsätze 229 Mio. $ (vgl. 181)
  
• Verlust 116 Mio. $ (vgl. 68)
  

"2019 Revenue: Net total revenue for 2019 is anticipated to increase by more than 50% over 2018 to approximately $350 million, mostly from U.S. sales of Vascepa.  Amarin believes that continued quarterly variability in revenues is likely. This guidance assumes that the timing of the expanded label for Vascepa which Amarin is seeking, subject to FDA approval, will not be available until late 2019 or early 2020 such that the expanded label has little or no impact on revenue growth in 2019."

investor.amarincorp.com/news-releases/...r-and-full-year-2018

Mega news, Vascepa von Amarin von der amerikanischen Diabetiker Organisation als standard of care aufgenommen, Millionen Diabetiker als Zielgruppe:

finance.yahoo.com/news/...tes-association-2019-090000025.html

Amarin meldet Zahlen für Q1/19

• Umsätze 73 Mio. $
  
• Verlust 24 Mio. $
  

investor.amarincorp.com/news-releases/...results-and-provides

finance.yahoo.com/news/3-top-mid-cap-stocks-113100104.html

H.C. Wainwright Survey Shows Substantial Runway For Amarin Corporation's (AMRN) Vascepa
June 26, 2019 8:21 AM
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $51.00 price target on Amarin Corporation (NASDAQ: AMRN) after conducted ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments

Vascepa Update & Anhebung der Umsatzprognose

• Q2/19 Umsatzausblick 97-101 Mio. $
  
• H1/19 Umsatzprognose 170-174 Mio. $
  
• für 2019 wird die Umsatzprognose von 350 Mio. $ auf 380-420 Mio. $ angehoben
  

investor.amarincorp.com/news-releases/...ng-commercialization

As background: Amarin stock skyrocketed last September after the company released robust results of its Reduce-It cardiovascular outcomes study. As I previously wrote, "The study showed that Vascepa ... reduced the risk of major adverse cardiovascular events by 25% in patients already taking statin drugs compared to those receiving a placebo, which is a highly statistically significant result."

AMRN Chart
AMRN Chart

Data by YCharts.

First Half of 2019

Amarin stock likely got a tailwind in the first half of the year from the strong overall market. That said, we can attribute its outperformance of the market to several catalysts, including:

   Jan. 9: Shares popped 8.1% following the company's optimistic presentation at the J.P. Morgan Healthcare Conference.
   Jan. 10: Shares soared 22.1% on market chatter about pharmaceutical giant Pfizer being interested in making a bid for Amarin.
   Feb. 22-27: Shares gained 21.5% in the four market days leading up to and including the company's release of its fourth-quarter and full-year 2018 results, driven by investor optimism about Vascepa sales on the heels of the Reduce-It study. Indeed, investors were right to be hopeful, as Vascepa's Q4 revenue rose 44% year over year to $77.3 million.
   May 29: Shares surged 11.6% after Amarin announced that the FDA had granted an expedited review of Vascepa for patients at risk of major adverse cardiovascular events. This moved the timetable for the agency's decision to six months after the application submission rather than the more usual 10 months.

Now what

Take heart, investors: The FDA's decision on Vascepa's label expansion should be less than three months away, in late September. Look for Amarin stock to react accordingly.

400 Mio. $ ADS Offering

• 22,22 Mio. ADS´s zu je 18$
  

investor.amarincorp.com/news-releases/...-depositary-shares-3

Amarin up 3% premarket on draft ICER report confirming Vascepa value
Jul. 24, 2019 9:07 AM ET|About: Amarin Corporation plc (AMRN)|By: Douglas W. House, SA News Editor

Amarin (NASDAQ:AMRN) perks up 3% premarket on light volume on the heels of a draft report from the non-profit Institute for Clinical and Economic Review (ICER) concluding that Vascepa (icosapent ethyl) and Johnson & Johnson's (NYSE:JNJ) blood thinner Xarelto (rivaroxaban) provide clinical benefit, reduce cardiovascular risk and "fall below commonly cited thresholds for cost-effectiveness." In other words, the products are priced appropriately for the value delivered.

JNJ is off a fraction premarket.

See all stocks on the move »

On July 18, AMRN announced the pricing of the underwritten public offering of 22.2 million shares at a price of $18 per shares. The gross proceeds of this offering are expected to be ~$400 million, before deducting expenses. Note that Amarin has also granted the underwriters a 30-day option to purchase up to an aggregate of 3.3 million additional shares.

As the company’s press release reveals, AMRN intends to use the net proceeds from the offering for multiple purposes. These include: (1) doubling its existing sales force for Vascepa to 800, increasing advertising, and supporting expanded commercial operations; (2) increasing the commercial supply of Vascepa from third-party drug product suppliers; and (3) for general corporate purposes.

“Amarin also may use a portion of the net proceeds to acquire strategic assets, although it currently has no agreements or commitments in this regard” the statement says.

Looking ahead the next catalysts to keep an eye on are as follows: 1) as you would expect, the potential FDA approval AMRN's supplemental new drug application (sNDA) seeking an expanded indication for Vascepa in the US based on the positive results of AMRN's REDUCE-IT study, 2) pick up in sales from expanded label as well as increased sales and promotional efforts, and 3) Amarin becoming profitable by 2020 (according to the analyst’s estimate).

Net-net, Chen reiterates her buy rating with a $35 price target (93% upside potential). “We continue to think that AMRN is an interesting asset in a consolidating space” she says.

• 101 Mio. $ Umsatz in Q2/19
  

investor.amarincorp.com/news-releases/...inancial-results-and